The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council

Detalles Bibliográficos
Autores principales: Tice, Jeffrey A, Touchette, Daniel R, Lien, Pei-Wen, Agboola, Foluso, Nikitin, Dmitriy, Pearson, Steven D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Perspectives on Value
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373007/
https://www.ncbi.nlm.nih.gov/pubmed/34949112
http://dx.doi.org/10.18553/jmcp.2022.28.1.119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373007/
https://www.ncbi.nlm.nih.gov/pubmed/34949112
http://dx.doi.org/10.18553/jmcp.2022.28.1.119

Ejemplares similares